Novo Nordisk slump wipes out last Wegovy-era gains after trial setback
Novo Nordisk shares fell more than 15% on Monday, wiping away the last gains Wegovy's launch had brought, after the drugmaker said its next-generation obesity drug CagriSema underperformed Eli Lilly's tirzepatide in a trial.
More info
